Peter Kolchinsky - Managing Partner - CrunchBase Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. He holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation. His graduate research investigated innate immune responses after intracerebral hemorrhage. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Adam Rosenberg is an Advisor for RA Capital Management. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Jeff Breay is a Head Trader at RA Capital Management. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. She is a CPA. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. He holds a BA from Cornell University and a PhD in Virology from Harvard University. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, and advocacy-oriented projects. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Analysis: Top Biotech VC Investors in 2021 Based on - Insider James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. from Harvard College and an M.B.A. from Harvard Business School. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Priscilla previously held a Senior Scientist role at Sanofi. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Jaime is an Executive Assistant at RA Ventures (RAVen). Samuel Chowdhury is a Software Engineerat RA Capital Management. Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. They will discuss the origins and history . Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Peter Kolchinsky, Research Alliance Corp II: Profile and Biography Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ben Dake is a Venture Associate at RA Capital Management. Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. James Schneider is the Deputy General Counsel at RA Capital Management. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Prior to BHP, Brigid was at In-Q-Tel (IQT), the strategic investment arm of the CIA and the US Intelligence Community; she co-founded IQT's Australian subsidiary, served as its Managing Director, and built an international program to support a global innovation initiative through investing in the Asian-Pacific region. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Pathways to | Harvard Office of Technology Development Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte. EXCLUSIVE : Robert Morgan's Talaria . He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Peter Kolchinsky Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. Joey ONeill is an Investor Services Associate at RA Capital Management. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Nadim Shohdy is an EIR at RA Capital. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Peter Kolchinsky - RA Capital Management - Insider Monkey The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley "He'll be 86 by the time it's over," said a woman in her 50s, noting the age Biden would be if he wins re-election and serves out a second term. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Linden Police Department Accident Reports, What Are Different Guidelines For Efficient Planning?, Gospel Radio Station In Augusta, Ga, Articles P
">